GlassScriptPhysician profile
Tyler Mcclintock
NPI 1861819864
$7,274.65
in general payments reported to CMS, 2019-2025
26 companies · $4,099 in 2025
The $4,099 reported for 2025 was more than what 89% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $53.71 · 2021: $396 · 2022: $712 · 2023: $1,009 · 2024: $1,006 · 2025: $4,099.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,121 · Consulting Fee: $2,225 · Travel and Lodging: $602 · Education: $166.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,120.50 |
| Consulting Fee | $2,225.00 |
| Travel and Lodging | $602.13 |
| Education | $165.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $2,317.90 | 2020-2025 | Spaceoar System, Spaceoar Vue System - 10ml, Lumenis Pulse 120h |
| Olympus America INC. | $1,816.65 | 2024-2025 | Itind System |
| Teleflex LLC | $1,542.07 | 2021-2025 | Urolift, Barrigel |
| Procept Biorobotics Corporation | $366.04 | 2022-2025 | Aquabeam System |
| Astellas Pharma US INC | $186.77 | 2025 | Xtandi |
| Ferring Pharmaceuticals INC. | $155.57 | 2025 | Adstiladrin |
| Axonics, INC. | $150.38 | 2022-2024 | Axonics |
| Palette Life Sciences, INC. | $109.00 | 2022 | |
| Biotissue Holdings INC. | $93.17 | 2024 | |
| Abbvie INC. | $72.81 | 2022-2025 | |
| Antares Pharma, INC. | $56.12 | 2024-2025 | Xyosted |
| Allergan, INC. | $51.69 | 2020-2021 | |
| Sumitomo Pharma America, INC. | $49.97 | 2024-2025 | Gemtesa |
| Telix Pharmaceuticals | $49.40 | 2024-2025 | Illuccix |
| Endo USA, INC. | $49.01 | 2025 | Aveed, Xiaflex |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gyrus Acmi, INC. | $39.22 | 2025 | Itind System |
| Endo Pharmaceuticals INC. | $35.23 | 2022-2023 | Xiaflex, Aveed |
| Immunitybio, INC. | $21.71 | 2025 | |
| Progenics Pharmaceuticals, INC. | $19.74 | 2025 | |
| Janssen Biotech, INC. | $17.51 | 2022 | |
| Myriad Genetic Laboratories, INC. | $16.76 | 2025 | Prolaris |
| Accord Healthcare, INC. | $15.67 | 2024 | |
| Mission Pharmacal Company | $15.64 | 2023 | Uribel |
| Laborie Medical Technologies Corp. | $13.60 | 2022 | |
| Halozyme INC | $13.02 | 2023 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tyler Mcclintock listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.